Amgen's TEPEZZA Receives UK Marketing Authorisation for Thyroid Eye Disease
Amgen announced that TEPEZZA (teprotumumab) has been granted marketing authorisation in the United Kingdom for adults with moderate-to-severe Thyroid Eye Disease (TED). This marks the first targeted treatment specifically for this condition in the UK.
Amgen's drug TEPEZZA (teprotumumab) has received marketing authorisation in the United Kingdom, becoming the first targeted therapy approved for adults suffering from moderate-to-severe Thyroid Eye Disease (TED). The approval was granted on May 12, 2025.
Thyroid Eye Disease is an autoimmune condition that affects the eyes, often occurring in individuals with thyroid dysfunction. It can lead to symptoms such as eye bulging, double vision, and pain, significantly impacting patients' quality of life.
TEPEZZA works by targeting the underlying cause of TED, addressing inflammation and tissue remodeling in the eye socket. Clinical trials demonstrated the drug's efficacy in reducing eye muscle inflammation and improving various measures of disease activity.
This authorisation follows previous approvals of TEPEZZA in other regions, highlighting its potential to address a significant unmet medical need in the TED patient population. Amgen is a global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics.